Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT04076891
Other study ID # RZL-012-FD-P2aUS-001.7
Secondary ID
Status Completed
Phase Phase 2
First received
Last updated
Start date June 28, 2018
Est. completion date May 2, 2019

Study information

Verified date September 2019
Source Raziel Therapeutics Ltd.
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This is an open label, 2 cohort, clinical trial in women with lipedema with substantial fat above the knee or women and men with nodular Dercum's disease. Each cohort will have 6 subjects who will receive RZL-012.


Description:

This is an open label, 2 cohort clinical trial in women with lipedema with substantial fat above the knee or women and men with nodular Dercum's disease. Each cohort will have 6 subjects who will receive RZL-012.

- The 1st cohort will be comprised of subjects with Dercum's disease

- The 2nd cohort will be comprised of subjects with lipedema with substantial fat above the knee.

Within each cohort, dosing of the subjects will progress consecutively from one individual to the other with a minimum of 7-days between subjects to assess safety. This study design will allow the physicians to monitor safety for at least 7 days prior to dosing the next subject. Cohort 2 will be conducted in a dose escalation manner and the decision to proceed to the next dose level will be made after reviewing all safety data collected by Day 14 within 2 ± 1d of the last dosed subject. The trial will proceed within a cohort provided that no more than one subject experiences intolerable side effects in a cohort, and based on the decision made by the Principal Investigator (PI) and the Medical Monitor.


Recruitment information / eligibility

Status Completed
Enrollment 12
Est. completion date May 2, 2019
Est. primary completion date May 2, 2019
Accepts healthy volunteers No
Gender All
Age group 20 Years to 65 Years
Eligibility Inclusion Criteria:

- 1. Post-menopausal (at least 2 years) women no more than 65 years old, with lipedema involving substantial fat above the knee or nodular Dercum's disease in such women and in men 20 - 65 years with nodular Dercum's disease.

2. For Dercum's disease subjects - at least 2 nodules to be injected of at least 2cm diameter each, as determined by ultrasound 3. For lipedema subjects - Significant subcutaneous fat above the knee as determined by circumference of 50cm 4. Generally considered healthy according to medical history, physical examination, ECG and laboratory evaluation with a special emphasis on metabolic parameters (fasting glucose concentration < 200 mg, normal blood pressure).

5. Subjects must be able to adhere to the visit schedule and protocol requirements and be available to complete the study.

6. Subjects must sign an informed consent indicating that they are aware of the investigational nature of the study.

Exclusion Criteria:

- 1. Unable to tolerate subcutaneous injection. 2. Subjects with uncontrolled cardiac, hepatic, renal or neurologic/psychiatric disorders, that in the opinion of the investigator, put the subject at significant risk, are not eligible.

3. Positive blood screen for Hepatitis B surface antigen (HbSAg), Hepatitis C virus (HCV), or Human immunodeficiency virus (HIV), or positive urine screen for alcohol or drugs of abuse (unless prescribed by a physician).

4. Subjects with a clinical history of primary or secondary immunodeficiency, autoimmune disease or subjects taking immunosuppressive drugs such as corticosteroids are ineligible.

5. As a result of medical review, physical examination, the PI (or medically qualified nominee) considers the subject unfit for the study.

6. Known sensitivity to components of the injection formulation. 7. Prior wound, tattoo or infection in the treated area. 8. Prior invasive treatment such as surgery or injectable drug at the RZL-012 injected area.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
RZL-012
The dosing regimen will be a single dose treatment injection of RZL-012 in multiple sites.

Locations

Country Name City State
United States University of Arizona Clinical and Translational Science Research Center Tucson Arizona

Sponsors (1)

Lead Sponsor Collaborator
Raziel Therapeutics Ltd.

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary The incidence of any Grade 3 or greater event intolerable side effect experienced in a cohort Trial will proceed as long as no more than one subject experiences an intolerable side effect in a cohort To 14 days
See also
  Status Clinical Trial Phase
Completed NCT04643392 - Physiotherapy Applications in Upper Extremity Lipedema
Completed NCT04492046 - Complex Decongestive Applications in Patients With Lipedema
Recruiting NCT05464927 - Visualizing Vascular Mechanisms of Lipedema
Completed NCT02907411 - Quadrivas Therapy® to Reduce Lipedema Subcutaneous Adipose Tissue (QUADRIVAS) N/A
Completed NCT06238791 - Plantar Pressure Analysis and Foot Biomechanics in Lipedema and Chronic Venous Disease
Completed NCT03710798 - Effect of an Low Carbon High Fat Diet on Pain- and Quality of Life in Patients With Lipedema N/A
Completed NCT03758651 - Williams Syndrome Strength, Hormones, Activity & Adiposity, DNA Programming, Eating Study
Not yet recruiting NCT04166084 - Trunk Stabilization Exercises at Lipoedema Patients N/A
Recruiting NCT05628948 - Vascular Lab Resource (VLR) Biorepository
Not yet recruiting NCT05944796 - Diathermy Effectiveness in Reducing Subcutaneous Adipose Tissue Affected by Lipedema N/A
Completed NCT05616962 - Collected Data of Medical Food, Vasculera or Diosmiplex, in Clinic Patients 20 to 70 Years Old Diagnosed With Lipedema N/A
Active, not recruiting NCT04632810 - Effect of Ketosis on Pain and Quality of Life in Patients With Lipedema N/A
Recruiting NCT05284266 - The National Lipedema Study N/A
Active, not recruiting NCT06338059 - Relationship Between Vitamin D and Vitamin B12 Levels and Neuropathic Pain in Lipedema
Completed NCT03492840 - Treatment of Women With Lipedema Involving Substantial Fat Knee of Women and Men With Nodular Dercum's Disease Phase 2
Recruiting NCT02838277 - Insight Into Subcutaneous Adipose Tissue Disorders N/A
Completed NCT05966779 - Physical Therapy in Lipedema Surgery
Recruiting NCT05488977 - The Effects of Endurance Training on Lipedema N/A
Completed NCT04213989 - Intermittent Pneumatic Compression in Women With Lipo-lymphedema (Lipedema With Swelling) N/A
Enrolling by invitation NCT00833599 - Imaging Lymphatic Function in Normal Subjects and in Persons With Lymphatic Disorders